Clean Yield Group’s Ionis Pharmaceuticals IONS Stock Holding History

Clean Yield Group’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-50	Closed	-$2K	–	478
2021 Q2	$2K	Buy	+50	New	+$1.96K	﹤0.01%	445

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Clean Yield Group's IONS Position: Q3 2021 in Review

Clean Yield Group sold out of Ionis Pharmaceuticals (IONS) in Q3 2021, closing a stake of 50 shares — an estimated $2K sold.

Clean Yield Group first reported a position in IONS in Q2 2021 and held it in 1 quarter. The position peaked at $2K in Q2 2021. 324 funds tracked by Wall St. Rank hold IONS as of Q3 2021.

Clean Yield Group reported no remaining Ionis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Clean Yield Group sold 50 Ionis Pharmaceuticals shares in Q3 2021, an estimated $2K.
Clean Yield Group first reported a position in Ionis Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Clean Yield Group's Ionis Pharmaceuticals position peaked at $2K in Q2 2021.
324 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2021.

Based on Clean Yield Group's 13F filing for Q3 2021, filed 27 Oct 2021.